

## Challenge of using Intranasal dexmedetomidine as a premedication modality in pediatric patients: A meta-analysis of randomized controlled trials

Mohamed Said Mostafa Elmeligy, Ahmed Mostafa Abdelhamid & Enas Wageh Mahdy

To cite this article: Mohamed Said Mostafa Elmeligy, Ahmed Mostafa Abdelhamid & Enas Wageh Mahdy (2023) Challenge of using Intranasal dexmedetomidine as a premedication modality in pediatric patients: A meta-analysis of randomized controlled trials, Egyptian Journal of Anaesthesia, 39:1, 579-594, DOI: [10.1080/11101849.2023.2236865](https://doi.org/10.1080/11101849.2023.2236865)

To link to this article: <https://doi.org/10.1080/11101849.2023.2236865>



© 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.



Published online: 21 Jul 2023.



Submit your article to this journal [↗](#)



Article views: 46



View related articles [↗](#)



View Crossmark data [↗](#)



# Challenge of using Intranasal dexmedetomidine as a premedication modality in pediatric patients: A meta-analysis of randomized controlled trials

Mohamed Said Mostafa Elmeligy<sup>a</sup>, Ahmed Mostafa Abdelhamid<sup>b</sup> and Enas Wageh Mahdy<sup>c</sup>

<sup>a</sup>Anesthesia Lecturer in Department of Anesthesia and Critical Care – Benha Faculty of Medicine –Benha University; <sup>b</sup>Anesthesia and Head of Critical Care Department –Benha Faculty of Medicine –Benha University; <sup>c</sup>Department of Anesthesia and Critical Care- Faculty of Medicine –Benha University

## ABSTRACT

**Background:** Intranasal dexmedetomidine premedication has been employed in children for controlling stress before induction of general anesthesia. Until now, the effect of intranasal dexmedetomidine in relation to other premedications remains incompletely studied.

**Objectives:** This study was conducted to study the effectiveness and safety of intranasal dexmedetomidine premedication in pediatrics.

**Sittings:** Meta-analysis-based study following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines.

**Methods:** Systematic searches of the databases MEDLINE, EMBASE, PubMed, and Cochrane were conducted to collect all published randomized, controlled, clinical trials in the last seven years which compare the intranasal dexmedetomidine premedication with other methods of premedication in different procedures.

**Results:** Twenty-five studies were collected for inclusion in this research including 2601 patients. The bias risk was low. Meta-analysis showed that the use of dexmedetomidine intranasally as a premedication when compared with other premedication regimes results in significant evidence of decreasing emergence agitation (RR = 0.64 [0.54, 0.77] 95% CI;  $I_2 = 84\%$ ;  $P = 0.0001$ ) fewer sedation scores (Mean difference = 51 [0.38, 0.65]; 95% CI;  $I_2 = 99\%$ ;  $P = 0.00001$ ), significantly less incidence of postoperative nausea and vomiting ((RR = 0.30 [0.20, 0.45] 95% CI;  $I_2 = 12\%$ ;  $P = 0.00001$ ), significantly decreased BP ((Mean difference = -2.28 [-3.42, -1.14]; 95% CI;  $I_2 = 88\%$ ;  $P = 0.0001$ ), and significantly decreased heart rate and (mean difference = -6.67 [-8.37, -4.97]; 95% CI;  $I_2 = 94\%$ ;  $P = 0.00001$ ).

**Conclusion:** Intranasal dexmedetomidine provided a satisfactory level of emergence agitation, more satisfactory sedation, more hemodynamic stability, and reduced the incidence of post-operative complications in relation to other premedications.

## ARTICLE HISTORY

Received 3 May 2023  
Accepted 11 July 2023

## KEYWORDS

Intranasal  
dexmedetomidine;  
premedication; pediatric;  
meta-analysis

## 1. Introduction

All over the world, there is a marked increase in the number of children undergoing surgery and diagnostic procedures that need sedation. Children undergoing surgeries often suffer from anxiety, pain, stress, unfamiliar persons and environment, fear of operating room setting, fasting, and the most important factor is separating from parents [1]. Which may lead to occurrence of many complications, such as preoperative hemodynamic instability, metabolic disorder, increased post-operative agitation, postoperative behavioral changes, postoperative sleep disorders, eating disorders, and nocturnal enuresis [2]. So, it is important to challenge anesthesia doctors to manage their pre-operative stress. Hence, premeditation is a good choice to eliminate pre-operative stress and help smooth induction of anesthesia without such complications.

Dexmedetomidine is considered an  $\alpha_2$ -adrenoceptor-activating drug used in preoperative sedation. Also, Dexmedetomidine has antiemetic and analgesic effects compared with other premedications [3]. Patients with preoperative Dexmedetomidine still arousal [4]. Furthermore, Dexmedetomidine also has fewer effects on respiration [5,6], so it is commonly used in intensive care in pediatrics [7]. On the other hand, Dexmedetomidine has been used in pediatric patients undergoing many procedures such as MRI, and it has been reported to be used safely in ambulatory sedation in pediatric [8–11].

There is now marked evidence to encourage the wide use of Dexmedetomidine as a premedication, sedative, and anesthetic aid in pediatric [12,13] for painless [14] and also painful procedures [15].

Premedication drugs used must have many properties like less-traumatic, tolerable route of administration and fewer side effects. Intranasal administered

**CONTACT** Mohamed Said Mostafa Elmeligy [mohmedsais808@yahoo.com](mailto:mohmedsais808@yahoo.com) Anesthesia lecturer in department of anesthesia and critical care – benha faculty of medicine –benha university, 01151717995

© 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.

Dexmedetomidine showed to be effective, tolerated safely, noninvasive route, and also has a rapid onset of action because of high vascularization of the nasal mucosa in the pediatric age group [16,17]

This study tried to observe the effect and safety of intranasal Dexmedetomidine as a premedication to decrease preoperative and postoperative stress in children.

## 2. Materials and methods

This study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [18]. No patient consent or ethical approval was needed because all analyzed data were collected from previously published literature.

## 3. Search strategy

To find all published randomized clinical trials, this meta-analysis searched MEDLINE, EMBASE, PubMed, and the Cochrane Library (from 2015:2022). The search was conducted by using Boolean operators (AND/OR) to link the following keywords: dexmedetomidine,

intranasal, and randomized trial. Studies were limited to humans with no language restrictions. Most papers search were done in May 2022, and another search was done in December 2022 to find more papers related to our article. The search process steps are described in Figure 1.

## 4. Eligibility criteria

With the aid of predetermined selection criteria, two reviewers independently identified all the studies. Disagreements that arose during the selection of the primary study were arbitrated by a third reviewer. The following criteria should be met by studies to be included in this meta-analysis:

- (1) Subject: pediatric patients who will receive premedication before going to surgery.
- (2) Interventions: studies which Analyze the impact of the dexmedetomidine premedication.
- (3) Comparisons: Control group received other premedication regimes
- (4) Outcomes: emergence agitation, sedation score, blood pressure, heart rate, and incidence of




Figure 1. (PRISMA) flow chart representing the search and selection process.

postoperative complications. The included study must have reported at least one of the results.

- (5) Type of literature: Clinically randomized controlled trials (RCTs) all published journals.

## 5. Selection criteria

After database search, the three reviewers checked the abstracts of the collected studies independently. After that, the reviewers checked the full text of the articles included in meta-analysis which matched the inclusion criteria. Any conflicts about the studies to include were resolved by the most senior author.

## 6. Exclusion criteria

Studies were excluded if they did not follow eligibility criteria, data reported in the form of conference abstracts, case reports, protocols, or reviews, or absent data, or The authors of the studies were inaccessible or did not respond when further data from their trials were sought.

## 7. Data extraction

Data were extracted from the included papers by the three authors independently. Extraction of data from the included randomized trial was performed and documented in a worksheet: the initial author, publication year, study design, sample size, setting, surgery type, intervention timing, type, dose, and route of all used premedication in addition to all relevant results. The incidence of emerging agitation served as the primary endpoint of this investigation. Secondary outcomes included sedation and side effects (hypotension and bradycardia).

## 8. Quality assessment and risk of bias

The reviewers evaluated the quality of each RCT using the Cochrane Handbook for Systematic Reviews of Interventions as a guide. The risk of bias table is explained in part-2, Chapter-8.5 of the handbook [19]. Other potential causes of bias. For each item: Yes, No, or Unclear was recorded. Any discrepancies were found and discussed in order to be addressed.

## 9. Statistical analysis

We carried out this meta-analysis to combine the outcomes of trials comparing the intranasal dexmedetomidine premedication with other premedication regimes used for sedation in a variety of surgical procedures using Review Manager (RevMan), Version 5.3, (Cochrane Collaboration, Oxford, UK) software. For heterogeneity measurement, chi-square test was used to calculate

P and I square values. No significant heterogeneity was identified if ( $P > 0.10$ ) and ( $I^2 < 50\%$ ), so a fixed-effect model for analysis of data was applied. When the heterogeneity was significant, a random-effects model is applied. For studies that only provide the interquartile range (IQR) for outcomes based on continuous measures, such (as emergence agitation and sedation score). By dividing the IQR by 1.35, we were able to determine the standard deviation (S.D.) from the data [20]. For dichotomous outcomes including postoperative nausea and vomiting, hypotension, and bradycardia, we estimated risk ratios (R.R.s) and their accompanying 95% confidence intervals (C.I.s). The definition of statistical significance used a two-sided alpha of 0.05, and clinical significance interpretations focused on C.

## 10. Identification of studies and characteristics of the studies

The database search resulted in the identification of 156 studies in total, and 97 studies were identified through other sources. After removing duplicate studies, 131 studies were acquired for additional evaluation. Then, after reviewing the titles and abstracts, 101 studies were eliminated. After reviewing the remaining 30 complete publications, 30 RCTs that satisfied all the inclusion criteria were ultimately found and included in this meta-analysis. There were 2601 patients involved in all 25 trials (Figure 1).

The involved studies were done from 2015 to 2022 in different countries; the fundamental features of the included studies were listed in Table 1.

## 11. Quality of the involved studies

To determine the probability of bias in RCTs, Cochrane Handbook tool was used. All RCTs defined their randomization approach using computer software and offered clear inclusion and exclusion criteria. The percentage of all included trials across every risk of bias item is displayed in Figure 2a.

The quality assessment of the study's methodology is summarized in Figure 2b.

In general, the risk of bias in the 25 studies was deemed to be minimal. (Figure 2a,b)

### 11.1. Outcomes for meta-analysis

After excluding unsuitable studies, the remarkable finding in studies involved in this meta-analysis was:

#### 11.1.1. Emergence agitation incidence

The incidence of emergence agitation was derived from 11 studies [22,29,32,33,37,39–41,43–45] in a total of 532 patients pooled that intranasal dexmedetomidine premedication showed a significant decrease in emergence agitation when compared to

Table 1. Characteristics of included studies.

Study ID	Intervention	Dose	Nm.	Age	Timing of injection	Surgery
Singla et al. 2015 [21]	IN DEX. IN midazolam	1 mcg/kg 0.2 mg/kg	30 30	5.86 ± 0.4 yrs. 5.9 ± 0.46 yrs.	30 min. before induction	Minor surgery
Mukherjee et al. 2015 [22]	IN DEX. IN Clonidine	1 mcg/kg 4 mcg/kg	40 40	5.3 ± 1.8 yrs. 5.6 ± 1.9 yrs.	45 min. before induction	Day case surgery
Rajalakshmi et al. 2015 [23]	IN DEX. IN Saline	2 mcg/kg 1 ml	30 30	4.83 ± 2.12 yrs. 5.17 ± 1.89 yrs.	In the holding are 23,29,32,33,37,39,41,43,44,45a Before the procedure	Cardiac surgeries Transthoracic echocardiography
Millar et al. 2016 [24]	Oral chloral hydrate IN DEX. 2 IN DEX. 3	70 mg/kg 2 mcg/kg 3 mcg/kg	50 50 50	13.6 ± 7.6 mon. 13.7 ± 8.6 mon. 15.4 ± 8.5 mon.	45–60 min. before anaesthetic induction Before the procedure	Elective suspension laryngoscopy Auditory brainstem response (ABR) testing
Lu et al. 2016 [25]	IN DEX. A placebo	1 mcg/kg 1 ml	40 41	43.6 ± 9.2 yrs. 45.9 ± 10.1 yrs.	45–60 min. before anaesthetic induction Before the procedure	Elective suspension laryngoscopy Auditory brainstem response (ABR) testing
Reynolds et al. 2016 [26]	IN DEX. + oral placebo	3 mcg/kg	44	23.3 mon. (19.5–27.2)	Before the procedure	Auditory brainstem response (ABR) testing
Sidhu et al. 2016 [27, 28]	Oral chloral hydrate + IN saline placebo IN DEX. IN clonidine	50 mg/kg 2 µg/kg 3 µg/kg	41 35 35 35	25.6 mon. (22.0–29.0) 5 [2–9], yrs. 5 [2–9], yrs. 5 [2–9], yrs.	30 min. prior to surgery	Various surgeries
Lin et al. 2016 [29]	IN DEX. IN DEX. IN DEX.	0.5 ml 1 mcg/kg 2 mcg/kg	30 30 30	4.75 ± 1.86 yrs. 4.04 ± 1.68 yrs. 4.15 ± 1.58 yrs.	45 min. before induction of anesthesia	Cataract surgery with sevoflurane
Wu et al. 2016 [30]	IN Saline IV Saline IN DEX. IN DEX. IV DEX. IV DEX.	Same volume Same volume 1 µg/kg 2 µg/kg 1 µg/kg 1 µg/kg	27 26 28 27	48 ± 4 yrs. 47 ± 4 yrs. 47 ± 5 yrs. 47 ± 5 yrs.	30 min. following nasal medication 40 min. before anesthesia induction 40 min. before anesthesia induction 10 min. before anesthesia induction	Elective hysterectomy Pediatric laceration repairs
Neville et al. 2016 [31]	IN DEX.	2 mcg/kg	20	3.44 yrs.	Prior to surgery	Pediatric laceration repairs
Abdelaziz et al. 2016 [32]	IN Midazolam IN DEX. IN Midazolam	0.4 mg/kg 1 mcg/kg 0.1 mg/kg	18 33 33	3.15 yrs. 2.68 ± 1.54 yrs. 2.48 ± 1.17 yrs.	Before entrance to the operation room	Strabismus surgery
Abd El-Hamid and Yassin. 2017 [33]	IN Saline IN DEX. IN Saline	1 ml 1 mcg/kg 0.5 ml in each nostril	32 43 43	2.78 ± 1.67 yrs. 4.4 ± 1.3 yrs. 4.2 ± 0.93 yrs.	After the induction of general anesthesia	Tonsillectomy and/or adenoidectomy under general anesthesia with sevoflurane
Shi et al. 2017 [34]	IN Saline 0.01 ml/kg + IV Saline 0.04 ml/kg + Propofol 2 mg/kg IN DEX. 0.1 mcg/kg + IV Saline 0.04 ml/kg + Propofol 2 mg/kg	IN Saline 0.01 ml/kg + IV Saline 0.04 ml/kg + Propofol 2 mg/kg IN DEX. 0.1 mcg/kg + IV Saline 0.04 ml/kg + Propofol 2 mg/kg	30 30	26.7 ± 4.8 yrs. 28 ± 4.1 yrs.	-IN drugs (45 min. before surgery) -IV drugs (During induction of GA)	Termination of first trimester pregnancy
Qiao et al. 2017 [35]	IN Saline 0.01 ml/kg + IV Sufentanil 0.1 mcg/kg + Propofol 2 mg/kg IN DEX. IN DEX. + Oral ketamine	IN Saline 0.01 ml/kg + IV Sufentanil 0.1 mcg/kg + Propofol 2 mg/kg IN DEX. IN DEX. + Oral ketamine	30 42 41	27.3 ± 4.5 yrs. 3.96 ± 1.50 yrs. 3.76 ± 1.36 yrs.	30 min. before the induction of anesthesia	Eye surgery under general anesthesia
Cao et al. 2017 [36]	Oral ketamine IN DEX. Oral chloral hydrate	6 mg/kg 2 mcg/kg 80 mg/kg	41 71 70	4.41 ± 1.28 yrs. 18 [10–25] mon. 14.5 (8.8–23.2) mon.	Before the procedure	Ophthalmic examinations

(Continued)

Table 1. (Continued).

Study ID	Intervention	Dose	Nm.	Age	Timing of injection	Surgery
Yuen et al. 2017 [37]	Chloral hydrate syrup+ IN Saline spray	50 mg/kg	107	24 mon.	30 min. before the procedure	Computerized tomography
Ghai et al. 2017 [38]	placebo syrup + IN DEX. Spray IN DEX.	3 mcg/kg 2.5 mcg/kg	87 30	32.5 mon. 3.8 ± 2.1 yrs.	30 min. after EMLA cream application	CT imaging
Millar et al. 2018 [39]	Oral Midazolam IN DEX.	0.5 mg/kg 2.5 mcg/kg	29 140	3.1 ± 1.3 yrs. 12.5 [8–17] mon.	Before the procedure	Outpatient TTEcho
GAO et al. 2018 [40]	Oral pentobarbital IN DEX.	5 mg/kg 2 mcg/kg	139 30	13 [9–17] mon. 46.2 ± 10.07 yrs.	30 min. before operation	Dental rehabilitation under GA
Li et al. 2018 [41]	IN Saline IN DEX. 1 IN DEX. 2 IN Saline	0.02 ml/kg 1 mcg/kg 2 mcg/kg In the same volume	30 30 30 30	43.6 ± 12.92 yrs. 4.47 ± 1.17 yrs. 4.53 ± 1.55 yrs. 4.37 ± 1.3 yrs.	25 to 40 min. before surgery	Adenoidectomy with or without tonsillectomy
Li et al. 2019 [42]	IN DEX. + buccal placebo	3 mcg/kg	136	35.0 (28.0–44.8) yrs.	30–40 min. before the procedure	Nonpainful Procedural Sedation in Children with Autism
Bi et al. 2019 [43]	IN DEX. + buccal midazolam IN DEX. IN Saline	3 mcg/kg + 0.2 mg 1 mcg/kg 0.01 ml/kg	139 20 20	34 (28.0–46.0) yrs. 17.2 ± 6.3 mon. 18.0 ± 6.6 mon.	25 min. before anesthesia induction	Removal of inhaled foreign bodies in children by flexible fiberoptic bronchoscopy
Aly,A(2020) [44]	IN KETAMINE IN DEX +IN KETAMINE	2 mcg/kg .5 mg/kg 3 mg/kg + 1 mcg/kg	88	2.8 ± 0.8 yrs	1 h before the procedure	Cardiac catheterization
Wang et al(2020) [45]	IN DEX. Oral Midazolam IN DEX.	2 mcg/kg 0.5 mg/kg 1mcg/kg	60 60	4.56 ± 0.59 yrs 5.14 ± 160 yrs	30 m before the procedure 30 m before the procedure	Dental rehabilitation under GA Various surgeries
Arun et al(2022) [46]	IN KETAMINE	.5 mg/kg				

other premedication treatments. (RR = 0.64 [0.54, 0.77] 95% CI;  $I^2 = 84\%$ ;  $P = 0.0001$ ) (Figure 3).

### 11.1.2. Sedation score

According to sedation scores and data extracted from eight studies [21,23–25,27,35,44,46] in total 321 patients Intranasal dexmedetomidine premedication showed fewer sedation scores when compared with premedication with other drugs (Mean difference = 51 [0.38, 0.65]; 95% CI;  $I^2 = 99\%$ ;  $P = 0.00001$ ). (Figure 4)

### 11.1.3. Nausea and vomiting

Postoperative nausea and vomiting incidence was collected from 11 studies [22,25,31–37,44,46] in a total of 498 patients showed that cases given intranasal dexmedetomidine premedication showed a significant decrease in postoperative nausea and vomiting incidence in comparison to other premedication techniques (RR = 0.30 [0.20, 0.45] 95% CI;  $I^2 = 12\%$ ;  $P = 0.00001$ ) (Figure 5).

### 11.1.4. Arterial blood pressure

We extracted the ABP data from 4 studies [21,22,27,44] in total 169 patients showed Intranasal dexmedetomidine premedication significantly decreased BP (Mean difference = -2.28 [-3.42, -1.14]; 95% CI;  $I^2 = 88\%$ ;  $P = 0.0001$ ) (Figure 6).

### 11.1.5. Heart rate

Heart rate was reported from 8 studies [21,22,24,27,35,43,44,46] in total 311 patients showed premedication with Intranasal dexmedetomidine also significantly lowered heart rate (Mean difference = -6.67 [-8.37, -4.97]; 95% CI;  $I^2 = 94\%$ ;  $P = 0.00001$ ) (Figure 7).

## 12. Discussion

Perioperative agitation is a significant and anxious problem, especially in children that need to be mentioned because it can result in a variety of complications and morbidities. Unfamiliar environment, fear of strangers persons and separation from the parents make the child nervous, fearful, agitated and aggressive and needs to increase in analgesics consumption unfortunately all have drawbacks [47].

There are many ways of administration of premedication such as oral, intravenous (IV), intramuscular (IM), rectal, and transmucosal. Each route has its flaws, for example, the oral route has less bioavailability, IM and IV routes are adjective and painful, and the rectal route is not comfortable. Sublingual and IN transmucosal routes have been demonstrated to be more well tolerated [48] in addition to being more effective and rapid medication administration methods due to their capacity to avoid first-pass metabolism and high mucosal vascularization [49] in contrast to the Intranasal administration of drugs has some disadvantages like nasal irritation, sneezing, and coughing, which can be Treated by utilizing a little amount of the drug's undiluted solution.

Highly selective  $\alpha_2$  adrenergic agonist DEX has some exceptional and unparalleled sedative properties [50], DEX has been investigated for pediatric sedation and anxiolysis when administered intravenously or by alternative routes, like intranasal (IN). Unlike other sedatives, DEX acts primarily in the locus coeruleus of the central nervous system, where it causes a somnolent sleep state that, according to an electroencephalogram, closely mimics non-REM sleep. Dexmedetomidine, therefore, causes conscious drowsiness, meaning that patients can be woken by a gentle tap or vocal order [51]. DEX is a desirable option for paediatric procedural sedation since it maintains spontaneous breathing, has few respiratory side effects, and




Figure 2a. Bias graph risk of involved studies.

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
Abdelaziz et al. 2016	+	+	+	+	+	+	+
Abd El-Hamid and Yassin. 2017	+	+	+	+	+	+	+
Aly. 2020	+	+	+	+	+	+	+
Arun et al. 2022	+	+	+	+	+	+	+
Bi et al. 2019	+	+	+	+	+	+	+
Cao et al. 2017	+	+	+	+	+	+	+
GAO et al. 2018	+	+	+	+	+	+	+
Ghai et al. 2017	+	+	+	+	+	+	+
Li et al. 2018	+	+	+	+	+	+	+
Li et al. 2019	+	+	+	+	+	+	+
Lin et al. 2016	+	+	+		+		+
Lu et al. 2016	+	+	+	+	+	+	+
Millar et al. 2016	+	+	+	+	+	+	+
Millar et al. 2018	+	+	+	+	+	+	+
Mukherjee et al. 2015	+	+	+	+	+	+	+
Neville et al. 2016	+	+	+	+	+	+	+
Qiao et al. 2017	+	+	+	+	+	+	+
Rajalakshmi et al. 2015	+	+					+
Reynolds et al. 2016	+	+	+	+	+	+	+
Shi et al. 2017	+	+	+	+	+	+	+
Sidhu et al. 2016	+	+	+	+	+	+	+
Singla et al. 2015	+	+	+	+	+	+	+
Wang et al. 2020	+	+	+	+	+	+	+
Wu et al. 2016	+	+	+	+	+	+	+
Yuen et al. 2017	+	+	+	+	+		+

Figure 2b. Bias summary risk depends on Cochrane risk of bias assessment tool; risk of bias domains includes mainly (bias of selection, performance, detection, attrition, and reporting).







Figure 3. Emergence agitation.



Study or Subgroup	IN DEX.		Others		Total	Weight	Mean Difference IV, Fixed, 95% CI	Year	Mean Difference IV, Fixed, 95% CI
	Mean	SD	Mean	SD					
<b>2.1.1 IN DEX. versus IN Midazolam</b>									
Singla et al. 2015	2.4	0.855	3.23	0.82	30	10.5%	-0.83 [-1.25, -0.41]	2015	
<b>Subtotal (95% CI)</b>					<b>30</b>	<b>10.5%</b>	<b>-0.83 [-1.25, -0.41]</b>		
Heterogeneity: Not applicable Test for overall effect: Z = 3.84 (P = 0.0001)									
<b>2.1.2 IN DEX. versus IN Saline</b>									
Rajalakshmi et al. 2015	3.23	0.568	1.13	0.345	30	33.4%	2.10 [1.86, 2.34]	2015	
Sidhu et al. 2016	3.36	0.938	1.14	0.355	35	17.1%	2.22 [1.89, 2.55]	2016	
Lu et al. 2016	4	0.74	6	0.74	41	18.2%	-2.00 [-2.32, -1.68]	2016	
<b>Subtotal (95% CI)</b>					<b>105</b>	<b>68.6%</b>	<b>1.04 [0.88, 1.21]</b>		
Heterogeneity: Chi <sup>2</sup> = 466.47, df = 2 (P < 0.00001); I <sup>2</sup> = 100% Test for overall effect: Z = 12.35 (P < 0.00001)									
<b>2.1.3 IN DEX. versus oral Chloral hydrate</b>									
Millar et al. 2016	13	5	14	9	50	0.2%	-1.00 [-3.85, 1.85]	2016	
<b>Subtotal (95% CI)</b>					<b>50</b>	<b>0.2%</b>	<b>-1.00 [-3.85, 1.85]</b>		
Heterogeneity: Not applicable Test for overall effect: Z = 0.69 (P = 0.49)									
<b>2.1.4 IN DEX. versus IN Clonidine</b>									
Sidhu et al. 2016	3.36	0.938	2.89	0.932	35	9.8%	0.47 [0.03, 0.91]	2016	
<b>Subtotal (95% CI)</b>					<b>35</b>	<b>9.8%</b>	<b>0.47 [0.03, 0.91]</b>		
Heterogeneity: Not applicable Test for overall effect: Z = 2.10 (P = 0.04)									
<b>2.1.5 IN DEX. versus oral Ketamine</b>									
Qiao et al. 2017	1	0.18	3	2.22	41	4.1%	-2.00 [-2.68, -1.32]	2017	
<b>Subtotal (95% CI)</b>					<b>41</b>	<b>4.1%</b>	<b>-2.00 [-2.68, -1.32]</b>		
Heterogeneity: Not applicable Test for overall effect: Z = 5.75 (P < 0.00001)									
<b>2.1.6 IN DEX. versus IN Ketamine</b>									
Aly. 2020	2	1.48	3	1.48	30	3.3%	-1.00 [-1.76, -0.24]	2020	
Arun et al. 2022	2.5	0.5	3.8	2	30	3.5%	-1.30 [-2.04, -0.56]	2022	
<b>Subtotal (95% CI)</b>					<b>60</b>	<b>6.8%</b>	<b>-1.15 [-1.68, -0.63]</b>		
Heterogeneity: Chi <sup>2</sup> = 0.31, df = 1 (P = 0.58); I <sup>2</sup> = 0% Test for overall effect: Z = 4.28 (P < 0.00001)									
<b>Total (95% CI)</b>					<b>321</b>	<b>100.0%</b>	<b>0.51 [0.38, 0.65]</b>		
Heterogeneity: Chi <sup>2</sup> = 636.45, df = 8 (P < 0.00001); I <sup>2</sup> = 99% Test for overall effect: Z = 7.34 (P < 0.00001) Test for subgroup differences: Chi <sup>2</sup> = 169.67, df = 5 (P < 0.00001), I <sup>2</sup> = 97.1%									

Figure 4. Sedation score.





Figure 5. Nausea and vomiting.




Study or Subgroup	IN DEX.		Total	Others		Total	Weight	Mean Difference IV, Fixed, 95% CI	Year	Mean Difference IV, Fixed, 95% CI
	Mean	SD		Mean	SD					
<b>4.1.1 IN DEX. versus IN Midazolam</b>										
Singla et al. 2015	102.83	6.54	30	106.67	6.92	30	11.2%	-3.84 [-7.25, -0.43]	2015	
<b>Subtotal (95% CI)</b>			<b>30</b>			<b>30</b>	<b>11.2%</b>	<b>-3.84 [-7.25, -0.43]</b>		
Heterogeneity: Not applicable Test for overall effect: Z = 2.21 (P = 0.03)										
<b>4.1.2 IN DEX. versus IN Saline</b>										
Sidhu et al. 2016	74.73	3.76	35	78.46	5.03	35	30.1%	-3.73 [-5.81, -1.65]	2016	
<b>Subtotal (95% CI)</b>			<b>35</b>			<b>35</b>	<b>30.1%</b>	<b>-3.73 [-5.81, -1.65]</b>		
Heterogeneity: Not applicable Test for overall effect: Z = 3.51 (P = 0.0004)										
<b>4.1.3 IN DEX. versus IN Clonidine</b>										
Mukherjee et al. 2015	61.7	6.4	40	66.1	7.2	40	14.6%	-4.40 [-7.39, -1.41]	2015	
Sidhu et al. 2016	74.73	3.76	35	72.93	4.36	35	35.8%	1.80 [-0.11, 3.71]	2016	
<b>Subtotal (95% CI)</b>			<b>75</b>			<b>75</b>	<b>50.4%</b>	<b>0.00 [-1.60, 1.61]</b>		
Heterogeneity: Chi <sup>2</sup> = 11.77, df = 1 (P = 0.0006); I <sup>2</sup> = 92% Test for overall effect: Z = 0.00 (P = 1.00)										
<b>4.1.4 IN DEX. versus IN Ketamine</b>										
Aly. 2020	73.5	6.8	29	82.2	8.6	30	8.3%	-8.70 [-12.65, -4.75]	2020	
<b>Subtotal (95% CI)</b>			<b>29</b>			<b>30</b>	<b>8.3%</b>	<b>-8.70 [-12.65, -4.75]</b>		
Heterogeneity: Not applicable Test for overall effect: Z = 4.32 (P < 0.0001)										
<b>Total (95% CI)</b>			<b>169</b>			<b>170</b>	<b>100.0%</b>	<b>-2.28 [-3.42, -1.14]</b>		
Heterogeneity: Chi <sup>2</sup> = 32.34, df = 4 (P < 0.00001); I <sup>2</sup> = 88% Test for overall effect: Z = 3.91 (P < 0.0001) Test for subgroup differences: Chi <sup>2</sup> = 20.57, df = 3 (P = 0.0001), I <sup>2</sup> = 85.4%										

Figure 6. Arterial blood pressure.

maintains upper airway tone. Dexmedetomidine also reduces the likelihood of EA in children undergoing MRIs while they are under general anaesthesia, without causing any respiratory distress or hemodynamic changes that might delay their release from the hospital [52].

Many studies have examined the route and dosage of DEX, which can be delivered intravenously, orally, intranasally, and intramuscularly. The best way to administer DEX is yet unknown; however, research has demonstrated that intranasal administration is safe, effective, and less intrusive



Study or Subgroup	IN DEX.			Others			Weight	Mean Difference IV, Fixed, 95% CI	Year	Mean Difference IV, Fixed, 95% CI
	Mean	SD	Total	Mean	SD	Total				
<b>5.1.1 IN DEX. versus IN Midazolam</b>										
Singla et al. 2015	94.23	9.33	30	99.93	5.71	30	18.9%	-5.70 [-9.61, -1.79]	2015	
Subtotal (95% CI)			30			30	18.9%	-5.70 [-9.61, -1.79]		
Heterogeneity: Not applicable Test for overall effect: Z = 2.85 (P = 0.004)										
<b>5.1.2 IN DEX. versus Oral Chloral hydrate</b>										
Millar et al. 2016	35	18	50	28	16	50	6.5%	7.00 [0.32, 13.68]	2016	
Subtotal (95% CI)			50			50	6.5%	7.00 [0.32, 13.68]		
Heterogeneity: Not applicable Test for overall effect: Z = 2.06 (P = 0.04)										
<b>5.1.3 IN DEX. versus IN Saline</b>										
Sidhu et al. 2016	106	7.1	35	123.4	22.9	35	4.6%	-17.40 [-25.34, -9.46]	2016	
Bi et al. 2019	136	21	20	151	14	20	2.4%	-15.00 [-26.06, -3.94]	2019	
Subtotal (95% CI)			55			55	7.0%	-16.58 [-23.04, -10.13]		
Heterogeneity: Chi <sup>2</sup> = 0.12, df = 1 (P = 0.73); I <sup>2</sup> = 0% Test for overall effect: Z = 5.04 (P < 0.00001)										
<b>5.1.4 IN DEX. versus IN Clonidine</b>										
Mukherjee et al. 2015	60.5	5.7	40	63.2	7.2	40	35.7%	-2.70 [-5.55, 0.15]	2015	
Sidhu et al. 2016	106	7.1	35	104.7	14	35	10.7%	1.30 [-3.90, 6.50]	2016	
Subtotal (95% CI)			75			75	46.4%	-1.78 [-4.27, 0.72]		
Heterogeneity: Chi <sup>2</sup> = 1.75, df = 1 (P = 0.19); I <sup>2</sup> = 43% Test for overall effect: Z = 1.40 (P = 0.16)										
<b>5.1.5 IN DEX. versus Oral Ketamine</b>										
Qiao et al. 2017	94.19	14.89	42	102.63	13.29	41	7.9%	-8.44 [-14.51, -2.37]	2017	
Subtotal (95% CI)			42			41	7.9%	-8.44 [-14.51, -2.37]		
Heterogeneity: Not applicable Test for overall effect: Z = 2.73 (P = 0.006)										
<b>5.1.6 IN DEX. versus IN Ketamine</b>										
Aly. 2020	86.9	18.3	29	98.2	10.6	30	4.9%	-11.30 [-18.96, -3.64]	2020	
Arun et al. 2022	78.8	7.34	30	112.57	14.64	30	8.4%	-33.77 [-39.63, -27.91]	2022	
Subtotal (95% CI)			59			60	13.4%	-25.48 [-30.14, -20.82]		
Heterogeneity: Chi <sup>2</sup> = 20.83, df = 1 (P < 0.00001); I <sup>2</sup> = 95% Test for overall effect: Z = 10.73 (P < 0.00001)										
Total (95% CI)			311			311	100.0%	-6.67 [-8.37, -4.97]		
Heterogeneity: Chi <sup>2</sup> = 125.91, df = 8 (P < 0.00001); I <sup>2</sup> = 94% Test for overall effect: Z = 7.68 (P < 0.00001) Test for subgroup differences: Chi <sup>2</sup> = 103.21, df = 5 (P < 0.00001), I <sup>2</sup> = 95.2%										

Figure 7. Heart rate.

than intravenous administration. Yuen et al. revealed that using 1 µg/kg Dexmedetomidine nose drops prior to surgery had a good sedative effect in 62% of the children having surgery [16]. **Li et al.** utilized 1.0 µg/kg Dexmedetomidine nasal drops 45 to 60 min prior to the onset of pediatric anaesthesia, which was just as effective as 0.2 mg/kg midazolam nasal drops [53]. Intranasal Dexmedetomidine can be utilized as a sedative agent in pediatric instances and can provide safe and effective premedication, according to the current meta-analysis, which is consistent with meta-analysis carried out by **Ex et al.**

1123 patients and 14 articles that were engaged the results of the meta-analysis revealed that the intranasal dexmedetomidine group's incidence of emergence agitation, adequate sedation upon parent separation, incidence of nausea and vomiting, and the incidence of laryngospasm was different from the control group [54]. Another meta-analysis done by **Yang et al.** makes our results stronger which included a total of 33 studies, involving 2,549 patients in this meta-analysis. Dexmedetomidine can minimize emerging agitation, regulate postoperative pain, reduce the need for rescue analgesics, and decrease the incidence of postoperative nausea and vomiting compared to saline [55]. In the line with our study, a randomized comparative study done by **Suvvari P et al.** that compare IN dexmedetomidine versus IN ketamine as premedication for the level of sedation in children undergoing radiation therapy observed that dexmedetomidine is better than ketamine in decreasing agitation and providing more sedation [56]. With the agreement, **Sun et al.** contrasted the intranasal use of midazolam and dexmedetomidine. They noticed that the dexmedetomidine group had better sedation after accepting the mask when compared to the midazolam group [57]. In addition, a meta-analysis made by **Li et al.** revealed that intranasal dexmedetomidine is an effective sedative approach rather than oral chloral hydrate for infants and toddlers undergoing diagnostic tests. Although there was a tendency toward decreased blood pressure and heart rate, intranasal dexmedetomidine may be a secure substitute for oral chloral hydrate as a sedative for young children [58].

Other than that, certain studies that have been published have not indicated a difference between the effectiveness of IN dexmedetomidine and other sedatives as premedication, such as **Gyanesh and colleagues** have not discovered any significant differences in how children react to the effectiveness of IN dexmedetomidine versus IN ketamine premedication for IV insertion [59]. Also, a study made by **Elsayed et al.** compared ketamine versus dexmedetomidine effect on sedation and anxiolysis given by intranasal route to pediatric cases going to adenotonsillectomy

and the results were both drugs give an effective sedation level with a better outcome of dexmedetomidine in sedation onset time and sedation score, and also little decrease in mean arterial pressure and heart rate. Additionally, there was a good degree of cannulation and parental separation scores in these sorts of procedures, and the pediatric parents were satisfied with the surgery and grateful to us for easing their children's and parents' worry and anxiety [60]. Remarkably, our results showed that dexmedetomidine results in decreasing blood pressure and heart rate and Dexmedetomidine's ability to lower sympathetic outflow and catecholamine levels in the blood can be used to explain this effect [61].

The strength of this study is that the data collection in our meta-analysis was systematic and carefully analyzed. The results confirmed the notion that dexmedetomidine had little impact on blood pressure and heart rate [62].


### 12.1. Limitation

On the other hand, it is important to think about certain potential restrictions. First, the heterogeneity among the studies we considered, which mostly resulted from different sedative medication dosages and, diagnostic procedures and the time of administration of Dexmedetomidine reaches its maximum effect of sedation at 30–45 min after intranasal administration, were still significant. We, therefore, conducted a meta-analysis using random effects models. Second, the age of the patients in the relevant research varied, which might have led to discrepancies in the studies since pharmacokinetics and pharmacodynamics differ between the ages of 3 months and 14 years, which may make the results distinguishable.

### Disclosure statement

No potential conflict of interest was reported by the author(s).

### ORCID

Mohamed Said Mostafa Elmeligy  <http://orcid.org/0009-0001-1991-0659>

### Data availability statement

On request, the corresponding author will provide the data used to support the study's conclusions.

### References

- [1] Watson AT, Visram A. Children's preoperative anxiety and postoperative behaviour. *Pediatric Anesthesia*.

- 2003;13(3):188–204. PubMed] [Google Scholar. doi: [10.1046/j.1460-9592.2003.00848.x](https://doi.org/10.1046/j.1460-9592.2003.00848.x)
- [2] Kain ZN, Mayes LC, Caldwell-Andrews AA, et al. Preoperative anxiety, postoperative pain, and behavioral recovery in young children undergoing surgery. *Pediatrics*. 2006;118(2):651–658. PubMed] [Google Scholar. doi: [10.1542/peds.2005-2920](https://doi.org/10.1542/peds.2005-2920)
  - [3] Lin TF, Yeh YC, Lin FS, et al. Effect of combining dexmedetomidine and morphine for intravenous patient-controlled analgesia. *Br J Anaesth*. 2009;102(1):117–122. doi: [10.1093/bja/aen320](https://doi.org/10.1093/bja/aen320)
  - [4] Colin PJ, Hannivoort LN, Eleveld DJ, et al. Dexmedetomidine pharmacokinetic–pharmacodynamic modelling in healthy volunteers: 1. Influence of arousal on bispectral index and sedation. *British Journal Of Anaesthesia*. 2017;119(2):200–210. doi: [10.1093/bja/aex085](https://doi.org/10.1093/bja/aex085)
  - [5] Venn RM, Hell J, Michael Grounds R, Michael Grounds R. Respiratory effects of dexmedetomidine in the surgical patient requiring intensive care. *Crit Care*. 2000;4(5):302. doi: [10.1186/cc712](https://doi.org/10.1186/cc712)
  - [6] Ebert TJ, Ph D, Hall JE, et al. The effects of increasing plasma concentrations of Dexmedetomidine in humans. *Anesthesiology*. 2000;93(2):382–394. doi: [10.1097/0000542-200008000-00016](https://doi.org/10.1097/0000542-200008000-00016)
  - [7] Baarslag MA, Allegaert K, Knibbe CAJ, et al. Pharmacological sedation management in the paediatric intensive care unit. *Journal Of Pharmacy And Pharmacology*. 2017;69(5):498–513. doi: [10.1111/jphp.12630](https://doi.org/10.1111/jphp.12630)
  - [8] Mason KP, Zurakowski D, Zgleszewski SE, et al. High dose dexmedetomidine as the sole sedative for pediatric MRI. *Paediatr Anaesth*. 2008;18(5):403–411. doi: [10.1111/j.1460-9592.2008.02468.x](https://doi.org/10.1111/j.1460-9592.2008.02468.x)
  - [9] Siddappa R, Riggins J, Kariyanna S, et al. High dose dexmedetomidine sedation for pediatric MRI. *Pediatric Anesthesia*. 2011;21(2):153–158. doi: [10.1111/j.1460-9592.2010.03502.x](https://doi.org/10.1111/j.1460-9592.2010.03502.x)
  - [10] Mason KP, Zgleszewski SE, Prescilla R, Zurakowski D. Hemodynamic effects of dexmedetomidine sedation for CT imaging studies. *Paediatr Anaesth*. 2008;18(5):393–402. doi: [10.1111/j.1460-9592.2008.02451.x](https://doi.org/10.1111/j.1460-9592.2008.02451.x)
  - [11] Li BL, Ni J, Huang JX, et al. Intranasal dexmedetomidine for sedation in children undergoing transthoracic echocardiography study - a prospective observational study. *Paediatr Anaesth*. 2015;25(9):891–896. doi: [10.1111/pan.12687](https://doi.org/10.1111/pan.12687)
  - [12] Gyanesh P, Haldar R, Srivastava D, et al. Meta-analysis of dexmedetomidine on emergence agitation and recovery profiles in children after sevoflurane anesthesia: Different administration and different dosage. *Anaesthesia*. 2014;24:12–8.
  - [13] Sun L, Guo R, SUN L. Dexmedetomidine for preventing sevoflurane-related emergence agitation in children: A meta-analysis of randomized controlled trials. *Acta Anaesthesiol Scand*. 2014;58(6):642–650. doi: [10.1111/aas.12292](https://doi.org/10.1111/aas.12292)
  - [14] Miller JW, Divanovic AA, Hossain MM, et al. Posologie et efficacité de la sédation intranasale à base de dexmédétomidine pour l'échocardiographie transthoracique chez l'enfant: une étude rétrospective. *Can J Anesth/J Can Anesth*. 2016;63(7):834–841. doi: [10.1007/s12630-016-0617-y](https://doi.org/10.1007/s12630-016-0617-y)
  - [15] Sheta SA, Al-Sarheed MA, Abdelhalim AA, et al. Intranasal dexmedetomidine vs midazolam for premedication in children undergoing complete dental rehabilitation: A double-blinded randomized controlled trial. *Paediatr Anaesth*. 2014;24(2):181–189. doi: [10.1111/pan.12287](https://doi.org/10.1111/pan.12287)
  - [16] Yuen VM, Hui TW, Irwin MG, et al. A randomised comparison of two intranasal dexmedetomidine doses for premedication in children. *Anaesthesia*. 2012;67(11):1210–1216. doi: [10.1111/j.1365-2044.2012.07309.x](https://doi.org/10.1111/j.1365-2044.2012.07309.x)
  - [17] Tug A, Hanci A, Turk HS, et al. Comparison of two different intranasal doses of dexmedetomidine in children for magnetic resonance imaging sedation. *Pediatr Drugs*. 2015;17(6):479–485. doi: [10.1007/s40272-015-0145-1](https://doi.org/10.1007/s40272-015-0145-1)
  - [18] Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement. *PLOS Med*. 2009;6(7):e1000097. doi: [10.1371/journal.pmed.1000097](https://doi.org/10.1371/journal.pmed.1000097)
  - [19] Higgins JPT, Thomas J, Chandler J, et al. *Cochrane handbook for systematic reviews of interventions version 6.3*. John Wiley & Sons. Cochrane; 2019. [10.1002/9781119536604](https://doi.org/10.1002/9781119536604)
  - [20] Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ*. 2011;343(oct18 2):d5928. doi: [10.1136/bmj.d5928](https://doi.org/10.1136/bmj.d5928)
  - [21] Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. *BMC Med Res Methodol*. 2014;14(1):135. doi: [10.1186/1471-2288-14-135](https://doi.org/10.1186/1471-2288-14-135)
  - [22] Deepak S, Chaudhary G, Dureja J, et al. Comparison of dexmedetomidine versus midazolam for intranasal premedication in children posted for elective surgery: a double-blind, randomised study. *Southern African J Anaesthesia Analgesia*. 2015;21(6):6, 154–157. doi: [10.1080/22201181.2015.1075937](https://doi.org/10.1080/22201181.2015.1075937)
  - [23] Mukherjee A, Das A, Roy Basunia S, et al. Emergence agitation prevention in paediatric ambulatory surgery: A comparison between intranasal Dexmedetomidine and Clonidine. *J Res Pharm Pract*. 2015 Jan-Mar;4(1):24–30. doi:[10.4103/2279-042X.150051](https://doi.org/10.4103/2279-042X.150051)
  - [24] Jayanthraj Rajalakshmi KS, Lokesh K. A study to evaluate the effects of intranasal dexmedetomidine as a premedicant in paediatric patients undergoing cardiac surgeries. *Egypt J Cardiothorac Anesth*. 2015;9(2):17–22. doi: [10.4103/1687-9090.165159](https://doi.org/10.4103/1687-9090.165159)
  - [25] Jeff M, Xue B, Hossain M, et al. Comparison of dexmedetomidine and chloral hydrate sedation for transthoracic echocardiography in infants and toddlers: a randomized clinical trial. *Paediatr Anaesth*. 2016;26(3):266–272. doi: [10.1111/pan.12819](https://doi.org/10.1111/pan.12819)
  - [26] Chengxiang L, Zhang L-M, Yuehong Z, et al. Xiangcai Ruan. Intranasal Dexmedetomidine as a Sedative Premedication for Patients Undergoing Suspension Laryngoscopy: A Randomized Double-Blind Study. *Plos One*. 2016 [Published online 2016 May 19];11(5):e0154192. DOI:[10.1371/journal.pone.0154192](https://doi.org/10.1371/journal.pone.0154192).
  - [27] Reynolds J, Rogers A, Medellin E, et al. A prospective, randomized, double-blind trial of intranasal dexmedetomidine and oral chloral hydrate for sedated auditory brainstem response (ABR) testing. *Paediatr Anaesth*. 2016;26(3):286–293. doi: [10.1111/pan.12854](https://doi.org/10.1111/pan.12854)
  - [28] Ghali AM, Mahfouz AK, Al-Bahrani M. Pre anesthetic medication in children: a comparison of intranasal dexmedetomidine versus oral midazolam. *Saudi J Anaesth*. 2011;5(4):387–391. doi: [10.4103/1658-354X.87268](https://doi.org/10.4103/1658-354X.87268)
  - [29] Gurkaran KS, Jindal S, Kaur G, et al. Comparison of Intranasal Dexmedetomidine with Intranasal

- Clonidine as a Premedication in Surgery. *Indian J Pediatr.* 2016 November;83(11):1253–1258. doi:10.1007/s12098-016-2149-4
- [30] Yiquan L, Chen Y, Huang J, et al. Efficacy of premedication with intranasal dexmedetomidine on inhalational induction and postoperative emergence agitation in pediatric undergoing cataract surgery with sevoflurane. *J Clin Anesth.* 2016;33:289–295. doi: 10.1016/j.jclinane.2016.04.027
- [31] Xiang W, Hang L-H, Wang H, et al. Intranasally Administered Adjunctive Dexmedetomidine Reduces Perioperative Anesthetic Requirements in General Anesthesia. *Yonsei Med J.* 2016 Jul 1;57(4):998–1005. doi: 10.3349/ymj.2016.57.4.998
- [32] Desiree NWN, Hayes KR, Ivan Y, et al. Double-blind Randomized Controlled Trial of Intranasal Dexmedetomidine versus Intranasal Midazolam as Anxiolysis Prior to Pediatric Laceration Repair in the Emergency Department. *AEM.* 2016 August;23(8):910–917. doi: 10.1111/acem.12998
- [33] Abdelaziz HM, Bakr RH, Kasem AA. Effect of intranasal dexmedetomidine or intranasal midazolam on prevention of emergence agitation in pediatric strabismus surgery: a randomized controlled study. *Egyptian Journal Of Anaesthesia.* 2016;32(3):285–291. doi: 10.1016/j.egja.2015.11.009
- [34] El-Hamid AM, Yassin HM. Effect of intranasal dexmedetomidine on emergence agitation after sevoflurane anesthesia in children undergoing tonsillectomy and/or adenoidectomy. *Saudi J Anaesth.* 2017;11(2):137–143. doi: 10.4103/1658-354X.203020
- [35] Hang S, Yang D, Liu J, et al. Intranasal dexmedetomidine in termination of first trimester pregnancy of suction evacuation. *Asian J Anesthesiol.* 2017. doi: 10.1016/j.aja.2017.09.001
- [36] Hui Q, Xie Z, Jia J. Pediatric premedication: a double-blind randomized trial of dexmedetomidine or ketamine alone versus a combination of dexmedetomidine and ketamine. *BMC Anesthesiol.* 2017;17(1):158. doi: 10.1186/s12871-017-0454-8
- [37] Cao Q, Lin Y, Xie Z, et al. Comparison of sedation by intranasal dexmedetomidine and oral chloral hydrate for pediatric ophthalmic examination. *Paediatr Anaesth.* 2017;27(6):629–636. doi: 10.1111/pan.13148
- [38] Yuen VM, Li BL, Cheuk DK, et al. A randomised controlled trial of oral chloral hydrate vs. intranasal dexmedetomidine before computerised tomography in children. *Anaesthesia.* 2017;72(10):1191–1195. doi: 10.1111/anae.13981
- [39] Ghai B, Jain K, Kumar Saxena A, et al. Comparison of oral midazolam with intranasal dexmedetomidine premedication for children undergoing CT imaging: a randomized, double-blind, and controlled study. *Paediatr Anaesth.* 2017;27(1):37–44. doi: 10.1111/pan.13010
- [40] Miller JWM, Ding LP, Gunter JBM, et al. Comparison of Intranasal Dexmedetomidine and Oral Pentobarbital Sedation for Transthoracic Echocardiography in Infants and Toddlers: A Prospective, Randomized, Double-Blind Trial. *Anesthesia Analgesia:* June 2018 -. 2018;126(6):- p 2009–2016. doi: 10.1213/ANE.0000000000002791
- [41] Gao L, Yun LIU, Xu-Dong YANG. Effect of intranasal dexmedetomidine for children undergoing dental rehabilitation under general anesthesia: a double-blinded randomized controlled trial. *J Peking University (Health Sciences).* 2018 Dec;50(6): 1078–1082.
- [42] Li-Qin L, Wang C, Hong-Yu X, et al. Effects of different doses of intranasal dexmedetomidine on preoperative sedation and postoperative agitation in pediatric with total intravenous anesthesia undergoing adenoidectomy with or without tonsillectomy. *Medicine (Baltimore).* 2018 Sep [Published online 2018 Sep 28];97(39):e12140. doi: 10.1097/MD.00000000000012140
- [43] Bi Lian L, Vivian Man-Ying Y, Na Z, et al. A Comparison of Intranasal Dexmedetomidine and Dexmedetomidine Plus Buccal Midazolam for Non-painful Procedural Sedation in Children with Autism. *J Autism Dev Disord.* 2019;49(9):3798–3806. doi: 10.1007/s10803-019-04095-w
- [44] Yanmei B, Yushan M, Ni J, et al. Efficacy of premedication with intranasal dexmedetomidine for removal of inhaled foreign bodies in children by flexible fiberoptic bronchoscopy: a randomized, double-blind, placebo-controlled clinical trial. *BMC Anesthesiol.* 2019;19(1):219. doi: 10.1186/s12871-019-0892-6
- [45] Aly AA. A comparison of intranasal ketamine, intranasal dexmedetomidine, and their combination as premedication in pediatric patients undergoing cardiac catheterization. *Res Opin Anesth Intensive Care.* 2020;7(4):232. Available at. doi: [https://doi.org/10.4103/roaic.roaic\\_85\\_19](https://doi.org/10.4103/roaic.roaic_85_19)
- [46] Li W, Huang L, Zhang T, et al. Comparison of intranasal dexmedetomidine and oral midazolam for premedication in pediatric dental patients under general Anesthesia: A randomised clinical trial. *Bio Med Res Int.* 2020;2020:1–7. Available at. doi: 10.1155/2020/5142913
- [47] Arun N, Choudhary A, Kumar M. Comparative study of intranasal dexmedetomidine versus intranasal ketamine as premedicant in children. *Cureus [Preprint].* 2022; Available at. doi: 10.7759/cureus.26572.
- [48] ECKENHOFF JE, EC JE. Relationship of anesthesia to postoperative personality changes in children. *Am J Dis Child.* 1953;86(5):587–591. doi: 10.1001/archpedi.1953.02050080600004
- [49] Kogan A, Katz J, Efrat R. Eidelman LA: Premedication with midazolam in young children: a comparison off-our routes of administration. *Pediatric Anesthesia.* 2002;12(8):685–689. doi: 10.1046/j.1460-9592.2002.00918.x
- [50] Sarkar MA. Drug metabolism in the nasal mucosa. *Pharm Res.* 1992;9(1):1–9. doi: 10.1023/a:1018911206646
- [51] Mahmoud MA, Mason KP, Mason KP. A forecast of relevant pediatric sedation trends. *Curr Opin Anesthesiol.* 2016;29(Suppl Supplement 1):S56–67. doi: 10.1097/ACO.0000000000000321
- [52] Mason KP, Lerman J, Lerman J. Dexmedetomidine in children: current knowledge and future applications. *Anesth Analg.* 2011;113(5):1129–1142. doi: 10.1213/ANE.0b013e31822b8629
- [53] Isik B, Arslan M, Tunga AD, et al. Dexmedetomidinedecreases emergence agitation in pediatric patients after sevofluraneanesthesia without surgery. *Paediatr Anaesth.* 2006;16(7):748–753. doi: 10.1111/j.1460-9592.2006.01845.x
- [54] Li A, V. Yuen M, Goulay-Dufay S, et al. Pharmacokinetic and pharmacodynamic study of intranasal and intravenous dexmedetomidine. *Br J Anaesth.* 2018;120(5):960–968. doi: 10.1016/j.bja.2017.11.100
- [55] Xu C, Zhang Y, Zhang T, et al. Efficacy and Safety of Intranasal Dexmedetomidine During Recovery from Sevoflurane Anesthesia in Children: A Systematic



- Review and Meta-analysis. *Clin Neuropharmacol.* 44 (5):157–168. doi: [10.1097/WNF.0000000000000466](https://doi.org/10.1097/WNF.0000000000000466)
- [56] Yang X, Hu Z, Peng F, et al. Effects of Dexmedetomidine on Emergence Agitation and Recovery Quality Among Children Undergoing Surgery Under General Anesthesia: A Meta-Analysis of Randomized Controlled Trials. *Front Pediatr.* 2020;8 (580226). doi: [10.3389/fped.2020.580226](https://doi.org/10.3389/fped.2020.580226)
- [57] Suvvari P, Mishra S, Bhatnagar S, et al. Comparison of intranasal dexmedetomidine versus intranasal ketamine as premedication for level of sedation in children undergoing radiation therapy: a prospective, randomised, double-blind study. *Turk J Anaesthesiol Reanim.* 2020;3 (3):215–222. doi: [10.5152/TJAR.2019.45087](https://doi.org/10.5152/TJAR.2019.45087)
- [58] Sun Y, Lu Y, Huang Y, et al. Is dexmedetomidine superior to midazolam as a premedication in children? A meta-analysis of randomized controlled trials. *Paediatr Anaesth.* 2014;24(8):863–874. doi: [10.1007/s00540-013-0001-1](https://doi.org/10.1007/s00540-013-0001-1)
- [59] Li L, Zhou J, Yu D, et al. Intranasal dexmedetomidine versus oral chloral hydrate for diagnostic procedures sedation in infants and toddlers: A systematic review and meta-analysis. *Medicine.* 2020;99(9):9(e19001). doi: [10.1097/MD.00000000000019001](https://doi.org/10.1097/MD.00000000000019001)
- [60] Gyanesh P, Haldar R, Srivastava D, et al. Singh PK: Comparison between intranasal dexmedetomidine and intranasal ketamine as premedication for procedural sedation in children undergoing MRI: a double-blind, randomized, placebo-controlled trial. *J Anesth.* 2014;28(1):12–18. doi: [10.1007/s00540-013-0001-1](https://doi.org/10.1007/s00540-013-0001-1)
- [61] Elshafeey AEAM, Youssef GFK, Elsalam EHA, et al. Comparative study between intranasal dexmedetomidine and intranasal ketamine as a premedication for anxiolysis and sedation before pediatric general anesthesia. *Ain-Shams J Anesthesiol.* 2020;12(1):51. doi: [10.1186/s42077-020-00104-8](https://doi.org/10.1186/s42077-020-00104-8)
- [62] Talke P, Chen R, Thomas B, et al. The hemodynamic and adrenergic effects of perioperative dexmedetomidine infusion after vascular surgery. *Anesth Analg.* 2000;90(4):834–839. doi: [10.1097/00000539-200004000-00011](https://doi.org/10.1097/00000539-200004000-00011)